Literature DB >> 6787991

Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.

E Vesterinen, N E Backas, K Pesonen, U H Stenman, T Laatikainen.   

Abstract

Medroxyprogesterone acetate (MPA) was administered orally for at least 6 months to 25 patients with endometrial adenocarcinoma starting 1 week after hysterectomy and bilateral ovariectomy. We measured serum concentrations of MPA during treatment and serum levels of LH, FSH, cortisol, and estrone before and during treatment with MPA. The serum levels of MPA 3--5 h after ingestion of a daily 100-mg dose of MPA at 08.00 h, varied considerably, the mean value (+/- SE) being 43 +/- 3.6 nmol/l range 15--119 nmol/l. Serum FSH levels rose after operation in the five premenopausal patients and remained elevated despite MPA treatment. In the 20 postmenopausal patients, however, initially high serum FSH and LH levels declined to half the starting values as a result of MPA treatment. After the administration of MPA for 6 months the mean serum cortisol and estrone concentrations at 08.00 a.m. had fallen to 78% and 82% of the mean values before treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787991     DOI: 10.1007/BF02111804

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  13 in total

1.  MANAGEMENT OF ADVANCED ENDOMETRIAL ADENOCARCINOMA WITH MEDROXYPROGESTERONE ACETATE.

Authors:  D G ANDERSON
Journal:  Am J Obstet Gynecol       Date:  1965-05-01       Impact factor: 8.661

2.  Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration.

Authors:  O Jänne; A Kauppila; K Kontula; P Syrjälä; R Vihko
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

3.  Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-ProveraR to women.

Authors:  S Jeppsson
Journal:  Contraception       Date:  1976-10       Impact factor: 3.375

4.  Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.

Authors:  T Laatikainen; U Nieminen; H Adlercreutz
Journal:  Acta Obstet Gynecol Scand       Date:  1979       Impact factor: 3.636

5.  The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.

Authors:  L Hellman; K Yoshida; B Zumoff; J Levin; J Kream; D K Fukushima
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

6.  Hormone-dependence of endometrial cancer.

Authors:  S B Gusberg
Journal:  Obstet Gynecol       Date:  1967-08       Impact factor: 7.661

7.  Effect of medroxyprogesterone acetate (Provera) on the metabolism and biological activity of testosterone.

Authors:  G G Gordon; A L Southren; S Tochimoto; J Olivo; K Altman; J Rand; L Lemberger
Journal:  J Clin Endocrinol Metab       Date:  1970-04       Impact factor: 5.958

8.  Serum levels of total dehydroepiandrosterone and total estrone in postmenopausal women with special regard to carcinoma of the uterine corpus.

Authors:  K Carlström; M G Damber; M Furuhjelm; I Joelsson; N O Lunell; B von Schoultz
Journal:  Acta Obstet Gynecol Scand       Date:  1979       Impact factor: 3.636

9.  In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.

Authors:  C Gupta; J Osterman; R Santen; C W Bardin
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

10.  Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma.

Authors:  J Bonte; J M Decoster; P Ide
Journal:  Acta Cytol       Date:  1977 Mar-Apr       Impact factor: 2.319

View more
  3 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; J J Pratt; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer.

Authors:  H Yamamoto; S Noguchi; K Miyauchi; H Inaji; S Imaoka; H Koyama; T Iwanaga
Journal:  Jpn J Cancer Res       Date:  1991-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.